Borrowings outstanding under the Revolving Credit Facility at August 31, 2021 were $104.5 million and there were approximately $12.6 million of outstanding letters of credit, which reduced the availability under this facility to $482.9 million as of August 31, 2021. There are no other terms or covenants limiting the availability of this facility.
In the first quarter of fiscal 2021, we received $57.2 million from the U.S. Treasury Department through the Payroll Support Program under the CARES Act. This funding included a $48.5 million cash grant, which is to be used exclusively for the continuation of payment of employee wages, salaries and benefits for employees of certain MRO facilities, and a low interest 10-year senior unsecured promissory note of $8.7 million. In fiscal 2021, we recognized the full amount of the grant as contra-expense within Cost of sales and Selling, general and administrative expenses. The Promissory Note was re-paid in full during the fourth quarter of fiscal 2021.
As of August 31, 2021, we also had other financing arrangements that did not limit our availability on the Revolving Credit Facility, including outstanding letters of credit of $11.6 million and foreign lines of credit of $10.1 million.
We maintain a Purchase Agreement with Citibank N.A. (“Purchaser”) for the sale, from time to time, of certain accounts receivable due from certain customers (the “Purchase Agreement”). Under the Purchase Agreement, the maximum amount of receivables sold is limited to $150 million and Purchaser may, but is not required to, purchase the eligible receivables we offer to sell. The term of the Purchase Agreement runs through February 22, 2022, however, the Purchase Agreement may also be terminated earlier under certain circumstances. The term of the Purchase Agreement shall be automatically extended for annual terms unless either party provides advance notice that they do not intend to extend the term.
We have no retained interests in the sold receivables, other than limited recourse obligations under certain circumstances, and only perform collection and administrative functions for the Purchaser. We account for these receivable transfers as sales under ASC 860, Transfers and Servicing, and de-recognize the sold receivables from our Condensed Consolidated Balance Sheet.
During the three-month periods ended August 31, 2021 and 2020, we sold $87.5 million and $129.0 million, respectively, of receivables under the Purchase Agreement and remitted $95.9 million and $147.6 million, respectively, to the Purchaser on their behalf. As of August 31, 2021 and May 31, 2021, we had collected cash of $3.8 million and $8.4 million, respectively, which was not yet remitted to the Purchaser as of those dates and was classified as Restricted cash on our Condensed Consolidated Balance Sheets.
At August 31, 2021, we were in compliance with all financial and other covenants under our financing arrangements.
Cash Flows from Operating Activities
Net cash provided by operating activities–continuing operations was $17.5 million in the three-month period ended August 31, 2021 compared to $39.8 million in the prior year period. The decrease from the prior period of $22.3 million was primarily attributable to the proceeds of a $48.5 million grant in the prior period from the Payroll Support Program of the CARES Act partially offset by a $25 million license fee paid to Unison Industries in the prior period for our expanded and extended exclusive distribution agreement.
Net cash used in operating activities–discontinued operations was $14.6 million in the three-month period ended August 31, 2021 compared to $0.9 million in the prior year period. The decrease from the prior period of $13.7 million was primarily attributable to the payment of the settlement with the U.S. Department of Justice for their False Claims Act investigation.
Cash Flows from Investing Activities
Net cash used in investing activities–continuing operations was $4.9 million during the three-month period ended August 31, 2021 compared to $1.7 million in the prior year period. The increase over the prior period was primarily related to investments in joint ventures of $2.7 million in the current year period.
Cash Flows from Financing Activities
Net cash used in financing activities–continuing operations was $5.5 million during the three-month period ended August 31, 2021 compared to $347.9 million in the prior year period. The decrease was primarily related to the repayment in the prior year period of our additional draw down on our Revolving Credit Facility. These funds were originally drawn in late fiscal 2020 as a precautionary measure in light of the economic and market uncertainty presented by COVID-19.